Karyopharm Therapeut (KPTI) 8.53 $KPTI
Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Fri Jun 10, 6:30AM CDT
- Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma -
KPTI: 8.53 (-0.60)
Karyopharm to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, is scheduled to present at the upcoming Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 3:00 p.m. ET.
KPTI: 8.53 (-0.60)
Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Thu May 19, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary activity of selinexor (KPT-330) and dexamethasone in combination with bortezomib (Velcade(R)), pomalidomide (Pomalyst(R)), or lenalidomide (Revlimid(R)) for the treatment of relapsed/refractory multiple myeloma (MM) (the STOMP study) has been accepted for presentation at the 21 Congress of the European Hematology Association (EHA) held June 9-12, 2016 in Copenhagen, Denmark. The abstract describes preliminary Phase 1b data in which responses were observed with selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1), and dexamethasone in combination with standard of care MM therapies in patients with heavily pretreated MM. Updated and detailed results from the study will be presented at the conference.
KPTI: 8.53 (-0.60)
Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Wed May 18, 4:40PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor (KPT-330), the Company's lead product candidate selinexor in development for hematological malignancies and solid tumors, have been selected for two poster presentations and one poster discussion at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago. Updated and detailed results from these studies will be presented at the conference. The abstracts, which represent both company- and investigator-sponsored clinical studies, describe data related to selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1). Posters to be presented include a Phase 2 clinical update with single-agent selinexor in recurrent glioblastoma, Phase 2 study design of single-agent selinexor in advanced liposarcoma and Phase 1 data for selinexor in multiple myeloma in combination with liposomal doxorubicin and dexamethasone.
KPTI: 8.53 (-0.60)
Karyopharm Therapeutics posts 1Q loss
Automated Insights - Mon May 09, 6:47AM CDT
NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Monday reported a loss of $27.1 million in its first quarter.
KPTI: 8.53 (-0.60)
Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress
GlobeNewswire - Mon May 09, 6:30AM CDT
Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma
KPTI: 8.53 (-0.60)
Why Earnings Season Could Be Great for Karyopharm Therapeutics (KPTI)
Zacks Equity Research - Zacks Investment Research - Fri May 06, 7:54AM CDT
Karyopharm Therapeutics (KPTI) looks like an exciting pick for investors as it is poised to beat at earnings season.
KPTI: 8.53 (-0.60)
Quanta Services (PWR) Q1 Earnings: Will It Disappoint?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 3:52PM CDT
Quanta Services (PWR) is expected to report first-quarter 2016 results on May 5. Let's see how things are shaping up for this announcement.
PWR: 23.47 (-0.63), PEGI: 21.16 (-1.03), AMID: 12.04 (-0.41), KPTI: 8.53 (-0.60)
Match Group (MTCH) Q1 Earnings Preview: What to Expect
Zacks Equity Research - Zacks Investment Research - Mon May 02, 6:04PM CDT
Match Group (MTCH) is set to report first-quarter 2016 earnings results after the closing bell on May 3. Let's see how things are shaping up for this announcement.
MTCH: 14.54 (-0.17), PEGI: 21.16 (-1.03), AMID: 12.04 (-0.41), KPTI: 8.53 (-0.60)
Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016 financial results and provide a company update on Monday, May 9, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, May 9, 2016 to discuss the financial results and recent business developments.
KPTI: 8.53 (-0.60)
Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury
GlobeNewswire - Wed Apr 20, 6:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced preclinical data demonstrating the activity of its Selective Inhibitor of Nuclear Export (SINE) compound, KPT-350, in rodent models of traumatic brain injury (TBI). These data were presented at the 2016 Annual Meeting of the American Academy of Neurology (AAN) taking place April 15-21 in Vancouver, Canada.
KPTI: 8.53 (-0.60)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 0.16 (unch), OMER: 10.75 (-0.09), ATHX: 2.38 (+0.03), KPTI: 8.53 (-0.60), CUR: 0.33 (-0.01)
Karyopharm Taps TransPerfect as eTMF and Functional TMF Provider
PR Newswire - Wed Apr 06, 9:00AM CDT
TransPerfect, a leading provider of global development and commercialization solutions to the life sciences industry, today announced that Karyopharm Therapeutics has implemented Trial Interactive as its electronic Trial Master File (eTMF).
KPTI: 8.53 (-0.60)
Karyopharm to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming 15 Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 8:40 a.m. ET.
KPTI: 8.53 (-0.60)
Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus
GlobeNewswire - Thu Mar 31, 7:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has been awarded a grant from the National Institute of Allergy and Infectious Disease (NIAID) to advance development of KPT-350, an oral Selective Inhibitor of Nuclear Export / SINE(TM) compound for the treatment of inflammatory, autoimmune and neurological diseases. The $225,000 grant will be used to conduct further preclinical studies of KPT-350 for the treatment of systemic lupus erythematosus, or lupus, a chronic, autoimmune disease that causes the body to create autoantibodies that attack and destroy healthy tissue, causing inflammation, pain, and damage in various parts of the body. These studies will be conducted in collaboration with Dr. Jenifer Anolik, MD, PhD, Associate Professor of Medicine at the University of Rochester.
KPTI: 8.53 (-0.60)
Karyopharm to Present Data on Oncology Pipeline at the 2016 American Association for Cancer Research Annual Meeting
GlobeNewswire - Wed Mar 16, 4:00PM CDT
Two Late-Breaking Posters Featuring the Company's Lead Drug Candidate, Selinexor (KPT-330), and Second Generation SINE Compound KPT-8602
KPTI: 8.53 (-0.60)
Karyopharm Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Progress
GlobeNewswire - Mon Mar 14, 6:30AM CDT
Company Continues to Expand its Leadership in SINE-based Therapies with Selinexor Clinical Advancement and Presentations of Encouraging Data for Earlier Stage Pipeline Programs
KPTI: 8.53 (-0.60)
Karyopharm to Report Fourth Quarter and Full Year 2015 Financial Results on March 14, 2016
GlobeNewswire - Mon Mar 07, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2015 financial results and provide a company update on Monday, March 14, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, March 14, 2016 to discuss the financial results and recent business developments.
KPTI: 8.53 (-0.60)
Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology
GlobeNewswire - Fri Mar 04, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the publication of results from a Phase 1 clinical trial of selinexor in patients with advanced solid tumors in the Journal of Clinical Oncology. This 189 patient study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a novel, oral small-molecule inhibitor of exportin 1 (XPO1/CRM1), and determined the recommended Phase 2 dose. Karyopharm is conducting multiple later-phase clinical trials to evaluate selinexor in hematological cancers and solid tumors and has also initiated a double-blinded, placebo-controlled, randomized Phase 2/3 study of single-agent selinexor in patients with liposarcoma (SEAL study). The Company also expects to initiate a double-blinded, randomized Phase 2/3 study of selinexor in combination with carfilzomib and low-dose dexamethasone in refractory multiple myeloma patients in mid-2016 (SCORE study).
KPTI: 8.53 (-0.60)
Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Fri Jun 10, 6:30AM CDT
- Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma -
KPTI: 8.53 (-0.60)
Karyopharm to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, is scheduled to present at the upcoming Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 3:00 p.m. ET.
KPTI: 8.53 (-0.60)
Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting
GlobeNewswire - Thu May 19, 6:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary activity of selinexor (KPT-330) and dexamethasone in combination with bortezomib (Velcade(R)), pomalidomide (Pomalyst(R)), or lenalidomide (Revlimid(R)) for the treatment of relapsed/refractory multiple myeloma (MM) (the STOMP study) has been accepted for presentation at the 21 Congress of the European Hematology Association (EHA) held June 9-12, 2016 in Copenhagen, Denmark. The abstract describes preliminary Phase 1b data in which responses were observed with selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1), and dexamethasone in combination with standard of care MM therapies in patients with heavily pretreated MM. Updated and detailed results from the study will be presented at the conference.
KPTI: 8.53 (-0.60)
Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Wed May 18, 4:40PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor (KPT-330), the Company's lead product candidate selinexor in development for hematological malignancies and solid tumors, have been selected for two poster presentations and one poster discussion at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago. Updated and detailed results from these studies will be presented at the conference. The abstracts, which represent both company- and investigator-sponsored clinical studies, describe data related to selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE(TM) compound that inhibits exportin 1 (XPO1). Posters to be presented include a Phase 2 clinical update with single-agent selinexor in recurrent glioblastoma, Phase 2 study design of single-agent selinexor in advanced liposarcoma and Phase 1 data for selinexor in multiple myeloma in combination with liposomal doxorubicin and dexamethasone.
KPTI: 8.53 (-0.60)
Karyopharm Therapeutics posts 1Q loss
Automated Insights - Mon May 09, 6:47AM CDT
NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Monday reported a loss of $27.1 million in its first quarter.
KPTI: 8.53 (-0.60)
Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress
GlobeNewswire - Mon May 09, 6:30AM CDT
Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma
KPTI: 8.53 (-0.60)
Why Earnings Season Could Be Great for Karyopharm Therapeutics (KPTI)
Zacks Equity Research - Zacks Investment Research - Fri May 06, 7:54AM CDT
Karyopharm Therapeutics (KPTI) looks like an exciting pick for investors as it is poised to beat at earnings season.
KPTI: 8.53 (-0.60)
Quanta Services (PWR) Q1 Earnings: Will It Disappoint?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 3:52PM CDT
Quanta Services (PWR) is expected to report first-quarter 2016 results on May 5. Let's see how things are shaping up for this announcement.
PWR: 23.47 (-0.63), PEGI: 21.16 (-1.03), AMID: 12.04 (-0.41), KPTI: 8.53 (-0.60)
Match Group (MTCH) Q1 Earnings Preview: What to Expect
Zacks Equity Research - Zacks Investment Research - Mon May 02, 6:04PM CDT
Match Group (MTCH) is set to report first-quarter 2016 earnings results after the closing bell on May 3. Let's see how things are shaping up for this announcement.
MTCH: 14.54 (-0.17), PEGI: 21.16 (-1.03), AMID: 12.04 (-0.41), KPTI: 8.53 (-0.60)
Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016 financial results and provide a company update on Monday, May 9, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, May 9, 2016 to discuss the financial results and recent business developments.
KPTI: 8.53 (-0.60)
Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury
GlobeNewswire - Wed Apr 20, 6:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced preclinical data demonstrating the activity of its Selective Inhibitor of Nuclear Export (SINE) compound, KPT-350, in rodent models of traumatic brain injury (TBI). These data were presented at the 2016 Annual Meeting of the American Academy of Neurology (AAN) taking place April 15-21 in Vancouver, Canada.
KPTI: 8.53 (-0.60)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 0.16 (unch), OMER: 10.75 (-0.09), ATHX: 2.38 (+0.03), KPTI: 8.53 (-0.60), CUR: 0.33 (-0.01)
Karyopharm Taps TransPerfect as eTMF and Functional TMF Provider
PR Newswire - Wed Apr 06, 9:00AM CDT
TransPerfect, a leading provider of global development and commercialization solutions to the life sciences industry, today announced that Karyopharm Therapeutics has implemented Trial Interactive as its electronic Trial Master File (eTMF).
KPTI: 8.53 (-0.60)
Karyopharm to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming 15 Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 8:40 a.m. ET.
KPTI: 8.53 (-0.60)
Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus
GlobeNewswire - Thu Mar 31, 7:30AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has been awarded a grant from the National Institute of Allergy and Infectious Disease (NIAID) to advance development of KPT-350, an oral Selective Inhibitor of Nuclear Export / SINE(TM) compound for the treatment of inflammatory, autoimmune and neurological diseases. The $225,000 grant will be used to conduct further preclinical studies of KPT-350 for the treatment of systemic lupus erythematosus, or lupus, a chronic, autoimmune disease that causes the body to create autoantibodies that attack and destroy healthy tissue, causing inflammation, pain, and damage in various parts of the body. These studies will be conducted in collaboration with Dr. Jenifer Anolik, MD, PhD, Associate Professor of Medicine at the University of Rochester.
KPTI: 8.53 (-0.60)
Karyopharm to Present Data on Oncology Pipeline at the 2016 American Association for Cancer Research Annual Meeting
GlobeNewswire - Wed Mar 16, 4:00PM CDT
Two Late-Breaking Posters Featuring the Company's Lead Drug Candidate, Selinexor (KPT-330), and Second Generation SINE Compound KPT-8602
KPTI: 8.53 (-0.60)
Karyopharm Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Progress
GlobeNewswire - Mon Mar 14, 6:30AM CDT
Company Continues to Expand its Leadership in SINE-based Therapies with Selinexor Clinical Advancement and Presentations of Encouraging Data for Earlier Stage Pipeline Programs
KPTI: 8.53 (-0.60)
Karyopharm to Report Fourth Quarter and Full Year 2015 Financial Results on March 14, 2016
GlobeNewswire - Mon Mar 07, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2015 financial results and provide a company update on Monday, March 14, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, March 14, 2016 to discuss the financial results and recent business developments.
KPTI: 8.53 (-0.60)
Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology
GlobeNewswire - Fri Mar 04, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the publication of results from a Phase 1 clinical trial of selinexor in patients with advanced solid tumors in the Journal of Clinical Oncology. This 189 patient study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a novel, oral small-molecule inhibitor of exportin 1 (XPO1/CRM1), and determined the recommended Phase 2 dose. Karyopharm is conducting multiple later-phase clinical trials to evaluate selinexor in hematological cancers and solid tumors and has also initiated a double-blinded, placebo-controlled, randomized Phase 2/3 study of single-agent selinexor in patients with liposarcoma (SEAL study). The Company also expects to initiate a double-blinded, randomized Phase 2/3 study of selinexor in combination with carfilzomib and low-dose dexamethasone in refractory multiple myeloma patients in mid-2016 (SCORE study).
KPTI: 8.53 (-0.60)
